US trails Europe in facilitating novel antibiotics development

While the Generating Antibiotic Incentives Now (GAIN) Act of 2012 has been a significant step in the right direction for encouraging novel antibiotics research, the US Food and Drug Administration (FDA) remains one step behind its European equivalent, the European Medicines Agency (EMA), according to an analyst with research and consulting firm GlobalData.

Photo: US trails Europe in facilitating novel antibiotics development

Marc C. Hansel, Ph.D., GlobalData’s Analyst covering Infectious Diseases, says that the GAIN Act has catalyzed investment from companies in the antibiotics business and has reinvigorated a stagnant pipeline, with the recent expedited approvals of two novel drugs, Sivextro and Dalvance.

Although these developments are positive, GlobalData believes that a number of unmet needs remain within the bacterial infectious diseases area, with novel treatments for multidrug-resistant (MDR) gram-negative bacteria in particularly high demand.
Hansel says: “The FDA has released draft guidance for the development of antibiotics, signifying its willingness to engage drug makers in the design of clinical trials for areas of high unmet medical need.
“Importantly, the GAIN Act is creating timely in-depth discussions between companies and the FDA, an invaluable communication that will improve the design of clinical studies by incorporating more relevant endpoints and pragmatic inclusion and exclusion criteria.”

Despite the FDA making strides in incentivizing companies to develop antimicrobial therapies, GlobalData believes that the agency needs to continue taking proactive action if it is to keep pace with progressive regulatory bodies in the EU, particularly the EMA. The latter organization has shown superior willingness to reform clinical trial design for novel antibiotics and provide guidance that prioritizes clinical feasibility.
Hansel explains: “Europe’s desire to tackle this challenge head-on is exemplified by the recent statement from UK Prime Minister David Cameron that the world could be ‘cast back into the dark ages of medicine’ unless action is taken to tackle the growing threat of resistance to antibiotics.

“The FDA will need to continue refining its practices in order to maintain a robust antibiotic pipeline and offer flexibility to encourage the targeting of the most dangerous pathogens. Crucially, the FDA must do more to further draw the vast research and development resources of Big Pharma into the antibiotics market by maximizing its commercial viability.”
 

15.07.2014

Read all latest stories

Related articles

Photo

New strategies against MRSA

A new paper by Shahriar Mobashery, Navari Family Professor in Life Sciences at the University of Notre Dame, and researchers in his lab provides important insights into promising new antibiotics…

Photo

MRSA in US hospitals

Arlington Medical Resources (AMR), a pharmaceutical market research firm, found that the number of patients treated with an antibiotic associated with MRSA-infections within U.S. acute care hospitals…

Photo

Know your enemy

Along with MRSA and ESBL bacteria, Clostridium difficile is causing a growing problem. Epidemics of a new C. difficile strain have already occurred in hospitals in North America, England and the…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH